The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Open accessAbstract
BACKGROUND: Pruritus in haemodialysis patients is an intractable disease and substantially impairs their quality of life. Based on the results of our earlier clinical study, we hypothesized that the micro-(mu) opioid system is itch-inducible, whereas the kappa (kappa) system is itch-suppressive. METHODS: The efficacy and safety of nalfurafine hydrochloride (a novel kappa-receptor agonist) were prospectively investigated by randomly (1:1:1) administering 5 or 2.5 microg of the drug or a placebo orally for 14 days using a double-blind design in 337 haemodialysis patients with itch that was resistant to currently available treatments, such as antihistamines. RESULTS: The mean decrease in the visual analogue scale (VAS) from baseline, the study's primary endpoint, was significantly larger in the 5-microg nalfurafine hydrochloride group (n = 114) than in the placebo group (n = 111, P = 0.0002, one-sided test at 2.5% significance level). The decrease in the VAS in the 2.5-microg group (n = 112) was also significantly larger than that in the placebo group (P = 0.0001). The incidence of adverse drug reactions (ADRs) was 35.1% in the 5-microg group, 25.0% in the 2.5-microg group and 16.2% in the placebo group. Moderate to severe ADRs were observed in 10 of the 226 patients. The most common ADR was insomnia (sleep disturbance), seen in 24 of the 226 nalfurafine patients. CONCLUSIONS: This Phase III, randomized, double-blind, placebo-controlled, parallel-group, prospective study based on VAS evaluations clearly showed that orally taken nalfurafine hydrochloride effectively reduced itches that were otherwise refractory to currently available treatments in maintenance haemodialysis patients, with few significant ADRs. This novel drug was officially approved for clinical use in January 2009 by the Ministry of Health, Labour and Welfare of Japan.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ikoma, A., Steinhoff, M., Ständer, S., Yosipovitch, G., & Schmelz, M. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1950 · Cited by 949
Pisoni, R. L., Wikstrom, B., Elder, S. J., Akizawa, T., Asano, Y., Keen, M. L., Saran, R., Mendelssohn, D. C., Young, E. W., & Port, F. K. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl461 · Cited by 641
Yosipovitch, G., Greaves, M. W., & Schmelz, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12570-6 · Cited by 388
Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients
Narita, I., Alchi, B., Omori, K., Sato, F., Ajiro, J., Saga, D., Kondo, D., Skatsume, M., Maruyama, S., Kazama, J. J., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000251 · Cited by 385
Wikstro[Combining Diaeresis]m, B. D., Gellert, R., Ladefoged, S. D., Danda, Y., Akai, M., Ide, K., Ogasawara, M., Kawashima, Y., Ueno, K., Mori, A., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020152 · Cited by 297
Randomised crossover trial of naltrexone in uraemic pruritus
Peer, G., Kivity, S., Agami, O., Fireman, E., Silverberg, D., Blum, M., & Iaina, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04176-1 · Cited by 295
μ-Opposing actions of the κ-opioid receptor
Pan, Z. Z. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01169-9 · Cited by 238
PAULI-MAGNUS, C., MIKUS, G., ALSCHER, D. M., KIRSCHNER, T., NAGEL, W., GUGELER, N., RISLER, T., BERGER, E. D., KUHLMANN, U., & METTANG, T. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v113514 · Cited by 225
Butorphanol for treatment of intractable pruritus
Dawn, A. G., & Yosipovitch, G. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.12.010 · Cited by 220
Antipruritic activity of the κ-opioid receptor agonist, TRK-820
Togashi, Y., Umeuchi, H., Okano, K., Ando, N., Yoshizawa, Y., Honda, T., Kawamura, K., Endoh, T., Utsumi, J., Kamei, J., et al. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01588-6 · Cited by 205
Cited by
Yosipovitch, G., & Bernhard, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1208814 · Cited by 405
Ständer, S., & Luger, T. A. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-44605-8_14 · Cited by 67
Metadata
- Authors
- Kumagai, H., Ebata, T., Takamori, K., Muramatsu, T., Nakamoto, H., & Suzuki, H.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11-19
- Volume
- 25
- Issue
- 4
- Pages
- 1251-1257
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2140123841
- Cited by
- 356
- References
- 21
- FWCI
- 15.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1093/ndt/gfp588
- The paper
- Kumagai, H., Ebata, T., Takamori, K., Muramatsu, T., Nakamoto, H., & Suzuki, H. (2010). Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfp588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.